Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV type 1-infected individuals administered different atazanavir dosesBOFFITO, Marta; MAITLAND, Desmond; DICKINSON, Laura et al.AIDS research and human retroviruses. 2006, Vol 22, Num 8, pp 749-756, issn 0889-2229, 8 p.Article

Mise au point concernant la résistance au saquinavir = Resistance to saquinavir: state of the artMORAND-JOUBERT, L.La Lettre du pharmacologue (Boulogne). 2002, Vol 16, Num 3, pp 93-97, issn 0984-452XArticle

Place du saquinavir dans le traitement antirétroviral de l'adulte infecté par le VIH-1 en 2001 = The place of saquinavir in the treatment of HIV infected adult in years 2001LEAUTEZ, S; BILLAUD, E.La Presse médicale (1983). 2001, Vol 30, Num 26, pp 1299-1303, issn 0755-4982Article

Entrapment and release of saquinavir using novel cationic solid lipid nanoparticlesKUO, Yung-Chih; CHEN, Hung-Hao.International journal of pharmaceutics (Print). 2009, Vol 365, Num 1-2, pp 206-213, issn 0378-5173, 8 p.Article

Steady-state pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patientsBOFFITO, Marta; DICKINSON, Laura; HILL, Andrew et al.Journal of acquired immune deficiency syndromes (1999). 2004, Vol 37, Num 3, pp 1376-1384, issn 1525-4135, 9 p.Article

The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavirCORBETT, Amanda H; ERON, Joseph J; FISCUS, Susan A et al.Journal of acquired immune deficiency syndromes (1999). 2004, Vol 36, Num 4, pp 921-928, issn 1525-4135, 8 p.Article

The effect of probenecid and MK-571 on the feto-maternal transfer of saquinavir in dually perfused human term placentaRAHI, Mea Melissa; MAARIT HEIKKINEN, Tuija; EERIK HAKALA, Kristo et al.European journal of pharmaceutical sciences. 2009, Vol 37, Num 5, pp 588-592, issn 0928-0987, 5 p.Article

Evasion of P-gp mediated cellular efflux and permeability enhancement of HIV-protease inhibitor saquinavir by prodrug modificationJAIN, Ritesh; AGARWAL, Sheetal; MAJUMDAR, Soumyajit et al.International journal of pharmaceutics. 2005, Vol 303, Num 1-2, pp 8-19, issn 0378-5173, 12 p.Article

Bioequivalence study of two oral tablet formulations containing saquinavir mesylate boosted with ritonavir in healthy male subjectsYERINO, Gustavo A; HALABE, Emilia K; ZINI, Elvira et al.Arzneimittel-Forschung. 2011, Vol 61, Num 8, pp 481-487, issn 0004-4172, 7 p.Article

Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytesJANNEH, Omar; BRAY, Patrick G; JONES, Elizabeth et al.Journal of antimicrobial chemotherapy (Print). 2010, Vol 65, Num 5, pp 906-916, issn 0305-7453, 11 p.Article

Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patientsVALER, Luisa; DE MENDOZA, Carmen; SORIANO, Vincent et al.Journal of medical virology. 2005, Vol 77, Num 4, pp 460-464, issn 0146-6615, 5 p.Article

Protease inhibitor-based regimens for HIV therapy : Safety and efficacyWALMSLEY, Sharon.Journal of acquired immune deficiency syndromes (1999). 2007, Vol 45, issn 1525-4135, S5-S13, SUP1Article

Gemini : A Noninferiority Study of Saquinavir/Ritonavir Versus Lopinavir/Ritonavir as Initial HIV-1 Therapy in AdultsWALMSLEY, Sharon; AVIHINGSANON, Anchalee; SCHUTZ, Malte et al.Journal of acquired immune deficiency syndromes (1999). 2009, Vol 50, Num 4, pp 367-374, issn 1525-4135, 8 p.Article

Can inhibition of proteasomes or NF-kappaB help control idiopathic nephrotic syndrome?WENDERFER, Scott E.Nephrology, dialysis, transplantation (Print). 2012, Vol 27, Num 5, pp 1698-1701, issn 0931-0509, 4 p.Article

Dose reduction effective in alleviating symptoms of saquinavir toxicitySTEPHAN, C; CARLEBACH, A; ROTTMANN, C et al.International journal of STD & AIDS. 2007, Vol 18, Num 2, pp 81-84, issn 0956-4624, 4 p.Article

Evaluation of an International Pharmacopoeia method for the analysis of saquinavir (mesilate) bulk drugs by liquid chromatographyYEKKALA, Raja; VANDENBOSCH, Lena; HOOGMARTENS, Jos et al.Journal of pharmaceutical and biomedical analysis. 2007, Vol 43, Num 3, pp 829-838, issn 0731-7085, 10 p.Article

Investigation of 2-Fold Disorder of Inhibitors and Relative Potency by Crystallizations of HIV-1 Protease in Ritonavir and Saquinavir MixturesOLAJUYIGBE, Folasade; DEMITRI, Nicola; GEREMIA, Silvano et al.Crystal growth & design. 2011, Vol 11, Num 10, pp 4378-4385, issn 1528-7483, 8 p.Article

Drug-Drug Interaction Study of Ketoconazole and Ritonavir-Boosted SaquinavirKAESER, Benoite; ZANDT, Hagen; BOUR, Fabrice et al.Antimicrobial agents and chemotherapy. 2009, Vol 53, Num 2, pp 609-614, issn 0066-4804, 6 p.Article

A Model Predicting Delivery of Saquinavir in Nanoparticles to Human Monocyte/Macrophage (Mo/Mac) CellsECE GAMSIZ, D; SHAH, Lipa K; DEVALAPALLY, Harikrishna et al.Biotechnology and bioengineering. 2008, Vol 101, Num 5, pp 1072-1082, issn 0006-3592, 11 p.Article

The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome functionPICCININI, Marco; RINAUDO, Maria T; ANSELMINO, Annalisa et al.Antiviral therapy (London). 2005, Vol 10, Num 2, pp 215-223, issn 1359-6535, 9 p.Article

Synthesis and anti-HIV activity of prodrugs derived from saquinavir and indinavirFARESE-DI GIORGIO, A; ROUQUAYROL, M; GREINER, J et al.Antiviral chemistry & chemotherapy. 2000, Vol 11, Num 2, pp 97-110, issn 0956-3202Article

Renin-angiotensin system inhibition in a patient having an overdose of HIV protease inhibitorDUVAL, X; PEYTAVIN, G; FOUQUERAY, B et al.AIDS (London). 1999, Vol 13, Num 14, pp 1983-1984, issn 0269-9370Article

Le saquinavir nouvelle formulation SGC (Soft Gel Capsule) = The new SGC (soft Gel Capsule) formulation of saquinavirKATLAMA, C.La Presse médicale (1983). 1999, Vol 28, Num 15, pp 815-818, issn 0755-4982Article

Acute hepatitis in a patient treated with saquinavir and ritonavir : Absence of cross-toxicity with indinavirVANDERCAM, B; MOREAU, M; HORSMANS, C et al.Infection. 1998, Vol 26, Num 5, issn 0300-8126, p. 313Article

Early experience with protease inhibitors in human immunodeficiency virus-infected childrenSAEZ-LLORENS, X; RAMILO, O.The Pediatric infectious disease journal. 1998, Vol 17, Num 8, pp 728-738, issn 0891-3668Article